Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...

(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) announced that the New Drug Application or NDA for ipilimumab injection (anti-CTLA-4 monoclonal antibody) has been accepted by the Center for Drug ...

The article by Doshi et al entitled “Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States” (JCO Clin Cancer ...

A clinical trial demonstrates that personalised cancer vaccines effectively target mutations in high-risk kidney cancer, ...

Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...

HIF2α gene expression and clinical outcomes in patients with clear cell renal cell carcinoma with and without sarcomatoid differentiation. Efficacy and safety of fruquintinib combined with serplulimab ...

A team has developed scSPOT, a new technique that reveals how immune cells called Tregs simultaneously control the immune system. The team identified key immune cells controlled by Tregs and found ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...